You are here

Rinvoq

AbbVie's Rinvoq passes midstage test in systemic lupus erythematosus, heads into phase 3

AbbVie's Rinvoq passes midstage test in systemic lupus erythematosus, heads into phase 3

Fierce Pharma

systemic lupus erythematosus

clinical trials

Flag link:

AbbVie's Rinvoq scores its 7th FDA nod, this one for Crohn's disease

AbbVie's Rinvoq scores its 7th FDA nod, this one for Crohn's disease

Fierce Pharma

Crohn's Disease

Flag link:

AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus

AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus

BioSpace

ulcerative colitis

clinical trials

Flag link:

AbbVie braces for 'greater erosion' of Humira franchise in second half of this year

AbbVie braces for 'greater erosion' of Humira franchise in second half of this year

Endpoints

Flag link:

Looking past Humira, AbbVie boosts sales forecasts for successor drugs

Looking past Humira, AbbVie boosts sales forecasts for successor drugs

BioPharma Dive

Richard Gonzalez

Flag link:

AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq

AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq

BioSpace

Flag link:

Where Will AbbVie Be in 3 Years?

Where Will AbbVie Be in 3 Years?

Motley Fool

Flag link:

This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

Motley Fool

ulcerative colitis

Flag link:

AbbVie Redeems Priority Review Voucher for Rinvoq Approval

AbbVie Redeems Priority Review Voucher for Rinvoq Approval

BioSpace

priority review

priority review vouchers

ulcerative colitis

Flag link:

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

Pharmaforum

clinical trials

Crohn’s disease

Flag link:

AbbVie's red-hot Rinvoq scores fourth FDA approval in five months

AbbVie's red-hot Rinvoq scores fourth FDA approval in five months

Fierce Pharma

ankylosing spondylitis

Flag link:

Ahead of Humira's patent cliff, AbbVie's Rinvoq notches third new use in 4 months

Ahead of Humira's patent cliff, AbbVie's Rinvoq notches third new use in 4 months

Fierce Pharma

ulcerative colitis

Flag link:

AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis

AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis

Endpoints

Flag link:

What This FDA News Could Mean for AbbVie's Stock

What This FDA News Could Mean for AbbVie's Stock

Motley Fool

Flag link:

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B

Fierce Pharma

Flag link:

Could This FDA Approval Create a Blockbuster Drug for AbbVie?

Could This FDA Approval Create a Blockbuster Drug for AbbVie?

Motley Fool

psoriatic arthritis

Flag link:

What to Make of the FDA's Latest Warning to AbbVie and Pfizer

What to Make of the FDA's Latest Warning to AbbVie and Pfizer

Motley Fool

Flag link:

Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change

Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change

Endpoints

Flag link:

AbbVie's Rinvoq notches Crohn's disease win amid classwide JAK safety concerns

AbbVie's Rinvoq notches Crohn's disease win amid classwide JAK safety concerns

Fierce Pharma

Crohn’s disease

Flag link:

Pages